Shire Development, LLC v. Watson Pharms., Inc.

E-Law Admin/ Februar 10, 2017/ Arzneimittelrecht Schweiz/ 0Kommentare

Shire Development, LLC v. Watson Pharms., Inc., 2016-1785

In a suit alleging defendant’s infringement by filing an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration seeking to market a generic version of plaintiff’s mesalamine drug, LIALDA, the district court’s finding of infringement is reversed where defendant’s ANDA product does not satisfy the Markush group requirements in claim 1(b).

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/02/10



  • United States Federal Circuit


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar